PhaseII study of the efficacy of DOCETAXEL plus RAMUCIRUMAB for NSCLC with brain metastasis
Latest Information Update: 30 Oct 2020
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms RAMNITA
- 27 Oct 2020 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2018 Trial design published in the Medicine.
- 19 Apr 2018 Status changed from not yet recruiting to recruiting.